^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
Excerpt:
...3) willing to do tumor biopsy for FGFR2 gene amplification via FISH test at central lab 2....
Trial ID:
Source:
Title:
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Published date:
10/16/2023
Excerpt:
Infigratinib in GC/GEJ patients with FGFR2 gene amplification has shown an inspiring clinical improvement, with acceptable tolerance, which is a potential first TKI regimen that precisely targeting in this population.
Trial ID:
Source:
Title:
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
Published date:
06/06/2023
Excerpt:
LianBio...announced positive topline results from a Phase 2a proof of concept trial evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification...The topline results from the gastric cancer and gastroesophageal junction adenocarcinoma cohort demonstrated a confirmed ORR of 25.0% (n=20)...The observed median duration of response (DOR) was 3.8 months. 57.1% of patients had received two prior lines of systemic therapy, 33.3% of patients had received three prior lines of systemic therapy, and 9.5% of patients had received more than three prior lines of systemic therapy.
Trial ID:
